Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
gptkb:Merck_KGa_A's_biosimilars_business
Baxter's infusion systems business Glenmark Pharmaceuticals' injectables business the biosimilars business of Merck KGa A |
| gptkbp:ceo |
gptkb:Michael_Sen
|
| gptkbp:employees |
over 40,000
|
| gptkbp:focus |
biosimilars
hospital products generic pharmaceuticals |
| gptkbp:focus_area |
gptkb:guidelines
gptkb:supply_chain_management gptkb:surgery research and development quality assurance home care patient safety sustainability telemedicine clinical trials corporate social responsibility data analytics oncology patient engagement market access pediatric care product innovation critical care global health initiatives emergency medicine elderly care pain management dialysis digital health solutions healthcare education transfusion medicine nutritional therapy healthcare policy advocacy regulatory affairs healthcare partnerships artificial intelligence in healthcare hospital pharmacy |
| gptkbp:founded |
gptkb:1999
|
| gptkbp:headquarters |
Bad Homburg, Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fresenius Kabi
|
| gptkbp:industry |
healthcare
|
| gptkbp:market |
global healthcare market
|
| gptkbp:operates_in |
more than 100 countries
|
| gptkbp:parent_company |
gptkb:Fresenius_SE_&_Co._KGa_A
|
| gptkbp:part_of |
gptkb:Fresenius_Group
|
| gptkbp:products |
gptkb:medical_devices
clinical nutrition intravenous drugs infusion solutions |
| gptkbp:revenue |
€6.5 billion (2020)
|
| gptkbp:subsidiary |
gptkb:Fresenius_SE_&_Co._KGa_A
|
| gptkbp:website |
www.fresenius-kabi.com
|
| gptkbp:bfsParent |
gptkb:Eisai
|
| gptkbp:bfsLayer |
5
|